This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scheidt-Nave, C. Articles by Pfeilschifter, J. Search for Related Content PubMed PubMed Citation Articles by Scheidt-Nave, C. Articles by Pfeilschifter, J. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Medline Plus Health Information Osteoporosis Hazardous Substances DB PARATHYROID HORMONE

Serum Interleukin 6 Is a Major Predictor of Bone Loss in Women Specific to the First Decade Past Menopause*

Departments of Social Medicine and Clinical Epidemiology (C.S.-N.) and Medicine I, Endocrinology, and Metabolism (C.S.-N., H.B., G.L.-B., H.W., M.J.S., R.Z.), University of Heidelberg Medical Center, D-69115 Heidelberg; and Department of Medicine, Kliniken Bergmannsheil, University of Bochum (J.P.), D-44789 Bochum, Germany

The role of serum interleukin 6 (IL-6) as a predictor of bone loss was examined in a population-based, longitudinal study of 137 postmenopausal German women, 52–80 yr old at baseline. Serum IL-6 and other biochemical parameters were measured in baseline blood or urine specimens. Repeat standardized measures of bone mineral density (BMD) at the femur (total hip) and the lumbar spine (L2–L4) were taken by dual x-ray absorptiometry an average of 3.3 yr apart. Medical history and anthropometric measures were obtained from standardized interview and examination. Crude and age-adjusted mean serum IL-6 levels were significantly lower in postmenopausal women with than without hormone replacement therapy at baseline. Among nonusers of hormone replacement therapy, serum IL-6 concentrations were highly predictive of femoral bone loss, independently of potential confounders and plasma sex hormones. Statistical interaction between serum IL-6 and menopausal age or menopausal age group (>10 vs. 10 yr) indicated that the effect of IL-6 on bone loss weakened with increasing distance from menopause and was no longer significant in women more than 10 yr after menopause. Among women up to 10 yr past menopause (n = 39), serum IL-6 was the single most important predictor of femoral bone loss, accounting for up to 34% of the total variability of change in BMD. The unadjusted linear model predicted an annual 1.34% (95% confidence interval, 0.67–2.01) decrease in total hip BMD per log unit increase in serum IL-6. A similar, although nonsignificant, effect of serum IL-6 on vertebral bone loss was restricted to women within the first 6 yr after menopause (n = 18). These epidemiological data show that serum IL-6 is a predictor of postmenopausal bone loss, and that the effect appears to be most relevant through the first postmenopausal decade. Whether these findings reflect pathogenetic differences between early and postmenopausal bone loss, and whether serum IL-6 also predicts fracture risk need further elucidation.

This article has been cited by other articles:

				J. A. Hyder, M. A. Allison, N. Wong, A. Papa, T. F. Lang, C. Sirlin, S. M. Gapstur, P. Ouyang, J. J. Carr, and M. H. Criqui Association of Coronary Artery and Aortic Calcium With Lumbar Bone Density: The MESA Abdominal Aortic Calcium Study Am. J. Epidemiol., January 15, 2009; 169(2): 186 - 194. [Abstract] [Full Text] [PDF]

				M K. Shea, G. E Dallal, B. Dawson-Hughes, J. M Ordovas, C. J O'Donnell, C. M Gundberg, J. W Peterson, and S. L Booth Vitamin K, circulating cytokines, and bone mineral density in older men and women Am. J. Clinical Nutrition, August 1, 2008; 88(2): 356 - 363. [Abstract] [Full Text] [PDF]

				C. Ding, V. Parameswaran, R. Udayan, J. Burgess, and G. Jones Circulating Levels of Inflammatory Markers Predict Change in Bone Mineral Density and Resorption in Older Adults: A Longitudinal Study J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1952 - 1958. [Abstract] [Full Text] [PDF]

				S. M. O'Brien A Possible Role of Recurrent Major Depression in Risk of Fracture Arch Intern Med, November 26, 2007; 167(21): 2370 - 2370. [Full Text] [PDF]

				M Bustamante, X Nogues, L Mellibovsky, L Agueda, S Jurado, E Caceres, J Blanch, R Carreras, A Diez-Perez, D Grinberg, et al. Polymorphisms in the interleukin-6 receptor gene are associated with bone mineral density and body mass index in Spanish postmenopausal women Eur. J. Endocrinol., November 1, 2007; 157(5): 677 - 684. [Abstract] [Full Text] [PDF]

				L. Ferrucci and D. Alley Obesity, Disability, and Mortality: A Puzzling Link Arch Intern Med, April 23, 2007; 167(8): 750 - 751. [Full Text] [PDF]

				G. P. Anderson COPD, asthma and C-reactive protein. Eur. Respir. J., May 1, 2006; 27(5): 874 - 876. [Full Text] [PDF]

				H.-P. Yu, T. Shimizu, Y.-C. Hsieh, T. Suzuki, M. A. Choudhry, M. G. Schwacha, and I. H. Chaudry Tissue-specific expression of estrogen receptors and their role in the regulation of neutrophil infiltration in various organs following trauma-hemorrhage J. Leukoc. Biol., May 1, 2006; 79(5): 963 - 970. [Abstract] [Full Text] [PDF]

				B. K. McFarlin, M. G. Flynn, W. W. Campbell, B. A. Craig, J. P. Robinson, L. K. Stewart, K. L. Timmerman, and P. M. Coen Physical activity status, but not age, influences inflammatory biomarkers and toll-like receptor 4. J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2006; 61(4): 388 - 393. [Abstract] [Full Text] [PDF]

				C E Todhunter, A Sutherland-Craggs, S A Bartram, P T Donaldson, A K Daly, R M Francis, J C Mansfield, and N P Thompson Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease Gut, November 1, 2005; 54(11): 1579 - 1584. [Abstract] [Full Text] [PDF]

				R. E. Scranton, M. Young, E. Lawler, D. Solomon, D. Gagnon, and J. M. Gaziano Statin Use and Fracture Risk: Study of a US Veterans Population Arch Intern Med, September 26, 2005; 165(17): 2007 - 2012. [Abstract] [Full Text] [PDF]

				S. Alesci, P. E. Martinez, S. Kelkar, I. Ilias, D. S. Ronsaville, S. J. Listwak, A. R. Ayala, J. Licinio, H. K. Gold, M. A. Kling, et al. Major Depression Is Associated with Significant Diurnal Elevations in Plasma Interleukin-6 Levels, a Shift of Its Circadian Rhythm, and Loss of Physiological Complexity in Its Secretion: Clinical Implications J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2522 - 2530. [Abstract] [Full Text] [PDF]

				C. L. Speyer, N. J. Rancilio, S. D. McClintock, J. D. Crawford, H. Gao, J. V. Sarma, and P. A. Ward Regulatory effects of estrogen on acute lung inflammation in mice Am J Physiol Cell Physiol, April 1, 2005; 288(4): C881 - C890. [Abstract] [Full Text] [PDF]

				L. Fontana, J. L. Shew, J. O. Holloszy, and D. T. Villareal Low Bone Mass in Subjects on a Long-term Raw Vegetarian Diet Arch Intern Med, March 28, 2005; 165(6): 684 - 689. [Abstract] [Full Text] [PDF]

				K. M. Prestwood, C. Unson, M. Kulldorff, and M. Cushman The Effect of Different Doses of Micronized 17{beta}-Estradiol on C-Reactive Protein, Interleukin-6, and Lipids in Older Women J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2004; 59(8): M827 - M832. [Abstract] [Full Text] [PDF]

				B. J. Ansell, M. Navab, S. Hama, N. Kamranpour, G. Fonarow, G. Hough, S. Rahmani, R. Mottahedeh, R. Dave, S. T. Reddy, et al. Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment Circulation, December 2, 2003; 108(22): 2751 - 2756. [Abstract] [Full Text] [PDF]

				D. Pierre-Paul and V. Gahtan Noncholesterol-Lowering Effects of Statins Vascular and Endovascular Surgery, September 1, 2003; 37(5): 301 - 313. [Abstract] [PDF]

				T. Ueland, K. Brixen, L. Mosekilde, L. Mosekilde, A. Flyvbjerg, and J. Bollerslev Age-Related Changes in Cortical Bone Content of Insulin-Like Growth Factor Binding Protein (IGFBP)-3, IGFBP-5, Osteoprotegerin, and Calcium in Postmenopausal Osteoporosis: A Cross-Sectional Study J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1014 - 1018. [Abstract] [Full Text] [PDF]

				S. L. Ferrari, L. Ahn-Luong, P. Garnero, S. E. Humphries, and S. L. Greenspan Two Promoter Polymorphisms Regulating Interleukin-6 Gene Expression Are Associated with Circulating Levels of C-Reactive Protein and Markers of Bone Resorption in Postmenopausal Women J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 255 - 259. [Abstract] [Full Text] [PDF]

				A. Rezaie-Majd, T. Maca, R. A. Bucek, P. Valent, M. R. Muller, P. Husslein, A. Kashanipour, E. Minar, and M. Baghestanian Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1194 - 1199. [Abstract] [Full Text] [PDF]

				J. Pfeilschifter, R. Koditz, M. Pfohl, and H. Schatz Changes in Proinflammatory Cytokine Activity after Menopause Endocr. Rev., February 1, 2002; 23(1): 90 - 119. [Abstract] [Full Text] [PDF]

				S.C. Manolagas, S. Kousteni, and R.L. Jilka Sex Steroids and Bone Recent Prog. Horm. Res., January 1, 2002; 57(1): 385 - 409. [Abstract] [Full Text] [PDF]